Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | histone deacetylase 7A | 0.00403658 | 0.578342 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.00370783 | 0.421658 | 0.729079 |
Plasmodium falciparum | histone deacetylase 2 | 0.00403658 | 0.578342 | 0.5 |
Leishmania major | histone deacetylase, putative | 0.00403658 | 0.578342 | 0.5 |
Trypanosoma cruzi | histone deacetylase, putative | 0.00403658 | 0.578342 | 0.5 |
Trypanosoma brucei | histone deacetylase, putative | 0.00403658 | 0.578342 | 0.5 |
Trypanosoma cruzi | histone deacetylase, putative | 0.00403658 | 0.578342 | 0.5 |
Plasmodium vivax | histone deacetylase, putative | 0.00403658 | 0.578342 | 0.5 |
Plasmodium falciparum | histone deacetylase, putative | 0.00403658 | 0.578342 | 0.5 |
Trypanosoma brucei | histone deacetylase 4 | 0.00403658 | 0.578342 | 0.5 |
Schistosoma mansoni | histone deacetylase hda2 | 0.00492128 | 1 | 1 |
Loa Loa (eye worm) | histone deacetylase | 0.00403658 | 0.578342 | 1 |
Brugia malayi | Histone deacetylase family protein | 0.00403658 | 0.578342 | 0.5 |
Brugia malayi | Histone deacetylase family protein | 0.00403658 | 0.578342 | 0.5 |
Echinococcus multilocularis | histone deacetylase 6 | 0.00492128 | 1 | 1 |
Echinococcus granulosus | histone deacetylase 6 | 0.00492128 | 1 | 1 |
Toxoplasma gondii | histone deacetylase HDAC1 | 0.00403658 | 0.578342 | 0.5 |
Plasmodium vivax | histone deacetylase 2, putative | 0.00403658 | 0.578342 | 0.5 |
Leishmania major | histone deacetylase, putative | 0.00403658 | 0.578342 | 0.5 |
Trypanosoma brucei | histone deacetylase 3 | 0.00403658 | 0.578342 | 0.5 |
Trypanosoma cruzi | histone deacetylase, putative | 0.00403658 | 0.578342 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (functional) | NOVARTIS: Antimalarial liver stage activity measured as a greater than 50% reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells at 10uM compound concentration, determined by immuno-fluorescence. | ChEMBL. | 22096101 | |
CC50 (functional) | > 100 uM | Huh7 cytotoxicity for Pf inhibitors | Novartis-GNF Malaria Box. | No reference |
CC50 | > 100 uM | NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7) | ChEMBL. | 18579783 |
EC50 (functional) | = 1.793 uM | W2 Pf proliferation inhibition | Novartis-GNF Malaria Box. | No reference |
EC50 (functional) | = 1.793 uM | NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay | ChEMBL. | 18579783 |
EC50 (functional) | > 10.8 uM | PF proliferation inhibition 3D7 | Novartis-GNF Malaria Box. | No reference |
EC50 (functional) | > 10.8 uM | NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay | ChEMBL. | 18579783 |
IFI promiscuity index | = 0.0463 | IFI promiscuity index | Novartis-GNF Malaria Box. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 | 18579783 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.